DDInter1544 DDInter1891
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.
Tucatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Tucatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Tucatinib {u} may lead to a major life threatening interaction when taken with {v} Olaparib
Tucatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Tucatinib may lead to a major life threatening interaction when taken with Ribociclib
Tucatinib may lead to a major life threatening interaction when taken with Olaparib